Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Beta Bionics, Inc. Common Stock

BBNX

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Last trade $14.80
Day change -$0.41 (-2.70%)
Day range $14.57 – $15.95
Volume 471,561
Market cap $827M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$826.92M
Price / earnings
—
Price / book
2.06×
Price / sales
6.5×
EV / sales
5.86×
EV / EBITDA
-8.29×

Profitability

Earnings per share
-$1.53
Return on assets
-18.73%
Return on equity
-20.71%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.92×
Quick ratio
8.22×
Cash ratio
2.48×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BBNX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$35.51M$32.01M$27.63M$32.12M$27.25M$23.24M$17.64M
Cost of revenue$15.17M$13.11M$11.19M$13.18M$12.13M$10.74M$8.67M
Gross profit$20.33M$18.9M$16.44M$18.94M$15.12M$12.5M$8.97M
Selling, general and administrative$34.97M$34.24M$30.35M$24.94M$23.97M$23.5M$20.02M
Research and development$11.98M$10.24M$10.36M$10.13M$8.2M$8.87M$7.59M
Total operating expenses$46.94M$44.48M$40.71M$35.07M$32.16M$32.38M$27.61M
Operating income-$26.61M-$25.58M-$24.27M-$16.12M-$17.04M-$19.87M-$18.64M
Interest expense$0$0$0$0$0$0$0
Income before taxes-$24.35M-$23.4M-$21.9M-$13.47M-$14.21M-$16.87M-$28.66M
Income taxes$0$0$0$0$0$0$0
Net income-$24.35M-$23.4M-$21.9M-$13.47M-$14.21M-$16.87M-$28.66M
Net income attributable to common shareholders-$24.35M-$23.4M-$21.9M-$13.47M-$14.21M-$16.87M-$28.66M
EBITDA-$25.72M-$24.87M-$23.69M-$15.59M-$16.66M-$19.53M-$18.34M
Basic earnings per share-$0.52-$0.53-$0.49-$0.30-$0.33-$0.39-$0.93
Diluted earnings per share-$0.52-$0.53-$0.49-$0.30-$0.33-$0.39-$0.93

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Beta Bio: 3 Key Takeaways for Long-Term Investors

Beta Bio reported Q3 2026 net sales of $35.5 million with strong pharmacy channel momentum. The company received FDA clearance for Mint, its tubeless patch pump launching in Q1 2027, expected to drive significant growth. Management raised full-year 2026 revenue guidance and highlighted that Mint's gross margins could exceed current patch pump products within three years. The company is resubmitting its 3D Intelligence dosing algorithm application after addressing FDA feedback.

GlobeNewswire Inc.

BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be entitled to compensation. The lead plaintiff deadline is November 3, 2026.

GlobeNewswire Inc.

Deadline Alert: Beta Bionics, Inc. Investors Have Until November 3, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

Beta Bionics, Inc. investors have until November 3, 2026 to request appointment as lead plaintiff in a securities fraud class action lawsuit. The complaint alleges the company failed to disclose material adverse facts regarding FDA Form 483 findings, including over 18,000 complaints and life-threatening hypoglycemic events that were not properly investigated or reported. The stock fell 37% on January 9, 2026 following disappointing preliminary fourth quarter 2025 financial results.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. alleging that the company made materially false and misleading statements regarding its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose FDA observations about quality management system deficiencies, device malfunctions, and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

GlobeNewswire Inc.

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

A class action lawsuit has been filed against Beta Bionics, Inc. for making materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased shares between July 30, 2025 and February 24, 2026 have until November 3, 2026 to apply as lead plaintiff.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.